CRP and cardiovascular disorder: It has demonstrated potential in reducing cardiovascular disease risk by lowering levels of pro-inflammatory markers such as C-reactive protein (CRP) and cytokines IL-6 and IL-1β, with its action mediated through the inhibition of C/EBP-δ and NF-κB signaling pathways [219] (Table 2).